Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913227 | 0.86 | MAPT (0.40) | DRD4DRD2DRD3MAPT | |
| Hydrochloric Acid SCHEMBL4899154 | 0.85 | MAPT (0.39) | DRD4DRD2DRD3MAPT | |
| SCHEMBL4907569 | 0.82 | MAPT (0.47) | DRD4MAPT | |
| SCHEMBL4901811 | 0.80 | KDM4E (0.38) | DRD4DRD2DRD3MAPT | |
| Hydrochloric Acid SCHEMBL4911304 | 0.79 | KDM4E (0.41) | DRD4DRD2DRD3MAPT | |
| SCHEMBL4908538 | 0.76 | HPGD (0.36) | — | |
| SCHEMBL4912381 | 0.75 | RPS6KB1 (0.37) | MAPT | |
| SCHEMBL4911095 | 0.74 | HIF1A (0.34) | MAPT | |
| SCHEMBL4909293 | 0.74 | TYMP (0.37) | MAPTPIK3CAMTOR | |
| SCHEMBL4908143 | 0.74 | HTR3E (0.48) | DRD4DRD3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119467-A1 | Purine Derivatives, Compositions Containing Them and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | claimed |
| US-20080119467-A1 | Purine Derivatives, Compositions Containing Them and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119467-A1 | Purine Derivatives, Compositions Containing Them and Use Thereof | TYMP, HPRT1, IMPDH1 | CHRNB2 4654/4885CHRNA4 4714/4885DRD4 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.